Toronto, Ontario--(Newsfile Corp. - August 9, 2019) - Beleave Inc. (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") is pleased to announce that on July 31, 2019 the company commenced the sale of its Blue Dream strain to medical patients under the Beleave Kannabis Corp. medicinal brand.
"Beleave is thrilled to be expanding its medicinal product offerings to include the extremely popular Blue Dream strain, which is available to medicinal patients in 5 gram units," said Beleave CEO, Bill Panagiotakopoulos. "The range of popular strains available for commercial production and distribution is an important advantage that helps us do what we do best - cultivating high-quality cannabis for our customers."
Blue Dream, a sativa-dominant hybrid originating in California, has achieved legendary status among West Coast strains. The product of crossing a Blueberry indica with the sativa Haze, Blue Dream delivers a sweet berry aroma redolent of its Blueberry parent and is a popular daytime medicine for patients requiring a high THC strain.
Beleave is excited to be providing patients with affordable and accessible medicinal cannabis products which currently include a number of dried cannabis and oil products that are already available.
Compassionate Pricing: Beleave offers a 20% discount off our products for those who meet the requirements of our Compassionate Pricing Program. We require a notice of assessment or proof of personal annual income.
Veteran Affairs: Beleave offers hassle-free access to medical cannabis for Canadian veterans and works hand in hand with Veterans Affairs to ensure seamless claim processing and prompt reimbursement. Patients will need to register with Beleave online and have their appropriate medical prescription from a qualified practitioner or a medical marijuana clinic before ordering.
Current or newly-registered Beleave medical patients are currently able to purchase Blue Dream, and other dried cannabis and oil products at https://shop.beleave.com.
To inquire about becoming a Beleave medical patient, please visit https://beleave.com/letsgetregistered
ABOUT BELEAVE INC.
Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully-licenced to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.
Beleave is developing new product lines, including cannabis-infused products, oils, vape pens, and other novel cannabis delivery methods for 2019. Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner. Through its majority ownership of Procannmed S.A.S., Beleave is fully licensed to cultivate, produce, and extract medical cannabis in Colombia positioning it to capitalize on exports and the expanding Latin American market. The Company has partnered with Canymed GmbH to supply the German market with medical cannabis.
Investor Relations Contact:
Interim Chief Financial Officer
Phone: 1 (647) 449 - 7352
This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/46828